Clavulanic Acid

證據等級: L5

預測適應症: 10 個

Clavulanic Acid: From β-Lactamase Inhibitor (Combination Antibiotic) to Ureaplasma Urethritis

One-Sentence Summary

Clavulanic acid is a β-lactamase inhibitor with no standalone registered indications; it is used exclusively in fixed-dose combinations such as amoxicillin-clavulanate (Augmentin) to protect β-lactam antibiotics from enzymatic degradation. The TxGNN model predicts it may be effective for Ureaplasma Urethritis, with 0 clinical trials and 0 supporting publications currently available for this indication. Critically, the mechanistic rationale for this prediction is absent — Ureaplasma species lack cell walls and are inherently resistant to β-lactam antibiotics — making this an L5 model-only prediction that warrants a Hold decision.

Quick Overview

Item	Content
Original Indication	No standalone registered indication (used exclusively in combination with β-lactam antibiotics)
Predicted New Indication	Ureaplasma Urethritis
TxGNN Prediction Score	99.93%
Evidence Level	L5
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Clavulanic acid is a suicide inhibitor of bacterial β-lactamase enzymes, derived from Streptomyces clavuligerus. Its mechanism works by binding irreversibly to the β-lactamase active site, preventing the enzyme from inactivating co-administered β-lactam antibiotics such as amoxicillin. On its own, clavulanic acid has negligible direct antibacterial activity — it is purely an adjuvant that restores efficacy to partner antibiotics against resistant organisms.

For this mechanism to be clinically relevant, the target pathogen must (a) produce β-lactamase enzymes, and (b) possess a cell wall susceptible to β-lactam attack. Ureaplasma urealyticum, the causative organism in Ureaplasma urethritis, satisfies neither condition. It is a wall-less bacterium of the class Mollicutes and is therefore inherently and completely resistant to all β-lactam antibiotics regardless of β-lactamase inhibitor co-administration. There is no mechanistic pathway — enzymatic, structural, or pharmacological — by which clavulanic acid could exert a therapeutic effect against Ureaplasma. Standard of care remains doxycycline or azithromycin.

The high TxGNN prediction score (99.93%) most likely reflects indirect knowledge graph associations — for example, connections between clavulanic acid-containing combinations and urinary tract infection nodes generally — rather than a genuine drug-disease biological relationship. This case illustrates a critical limitation of graph embedding models: a high confidence score can arise from network proximity without any mechanistic plausibility. All 10 predicted indications in this evidence pack share the same fundamental problem: clavulanic acid has no standalone therapeutic activity, and the AI model appears to be inheriting associations from its combination partner (amoxicillin) rather than evaluating the isolated compound.

Clinical Trial Evidence

Currently no related clinical trials registered for Clavulanic acid in Ureaplasma Urethritis.

Literature Evidence

Currently no related literature available for Clavulanic acid in Ureaplasma Urethritis.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: Every one of the 10 TxGNN-predicted indications lacks direct mechanistic support for clavulanic acid as a standalone agent; the top prediction (Ureaplasma urethritis) is mechanistically invalid, and the remaining predictions (including Pelvic Inflammatory Disease and broad ligament disease) at best reflect properties of the amoxicillin-clavulanate combination, not clavulanic acid alone. With zero supporting clinical trials or literature across all predicted indications, and no SAHPRA registration or South African market presence, there is insufficient basis to proceed.

To proceed, the following is needed:

Clarify the repurposing scope: Determine whether the intended research question concerns clavulanic acid as a standalone agent or as part of a fixed-dose combination (e.g., amoxicillin-clavulanate); these are fundamentally different pharmacological entities for the purposes of drug repurposing analysis
Re-run TxGNN using the combination entity: If the goal is to identify new indications for amoxicillin-clavulanate as a combination product, the TxGNN analysis should be repeated using the combination drug node, which is likely to yield more mechanistically coherent predictions
Obtain MOA data from DrugBank (ID: DB00766) to formally document the mechanism and confirm the limitations identified in this analysis
Obtain SAHPRA Professional Information (PI): Download and parse the PI to populate safety warnings, contraindications, and drug interaction data currently marked as unavailable
Explore novel mechanisms independently: If there is scientific interest in clavulanic acid beyond β-lactamase inhibition (e.g., emerging research on BlaC inhibition in Mycobacterium tuberculosis), this should be assessed via a dedicated literature search and expert pharmacology review, separate from the current TxGNN pipeline

⚠️ YMYL Disclaimer: This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Data cutoff: 2026-04-05.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.